
Diabete: dipeptyl peptidase-4 inhibitors and sulphonylureas, an association with potential risks
NewsIn the article published in the BMJ of may 2016, Francesco Salvo, researcher in the team “Pharmacoepidemiology and population impact of drugs” in the Bordeaux population health research center U1219, recalls the importance of compliance with recommendations regarding dipeptyl peptidase-4 inhibitors (DPP-4) and sulphonylureas when these drugs are associated in diabetics patients,. This article allows […]